The shares of Natco Pharma were trading higher by 1 per cent in a down market after the company informed the exchanges that it has launched Brivaracetam tablets under the brand Brecita in India.
The abovementioned tablets, developed by UCB Pharma, would be used for the treatment of epilepsy. The drug is currently marketed in India by Dr Reddy’s under the brand name ‘Briviact’. Epilepsy patients in India are estimated to be between 5 and 10 million, as per the guidelines for the management of epilepsy in India (GEMIND).
Natco Pharma’s Brecita tables will be made available in the strengths of 50 mg and 100 mg at prices of Rs 25 and Rs 35, respectively, the company stated in its press release to BSE.
At 3 pm on Friday, the stock of Natco Pharma was trading at Rs 812.60 per share, up by 1.30 per cent or Rs 10.40 per share, against a 3.44 per cent gain in the benchmark index. The 52-week high is recorded at Rs 995.05 while its 52-week low is Rs 450 on BSE.